查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
融合抑制剂市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)
市场调查报告书
商品编码
1208546

融合抑制剂市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)

Fusion Inhibitors Market (Indication: HIV/AIDS and COVID-19; and Route of Administration: Parenteral and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10个工作天内

价格

本报告提供全球融合抑制剂市场相关调查，提供市场概要，以及2022年～2031年的预测，各给药途径，各适应症，各流通管道，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 前提与调查手法

第3章 摘要整理:全球融合抑制剂市场

第4章 市场概要

  • 简介
  • 概要
  • 市场动态
  • 全球融合抑制剂市场分析与预测，2017年～2031年

第5章 主要洞察

第6章 全球融合抑制剂市场分析与预测，各给药途径

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测，各给药途径，2017年～2031年
    • 口服
    • 非口服
  • 市场魅力分析，各给药途径

第7章 全球融合抑制剂市场分析与预测，各适应症

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测，各适应症，2017年～2031年
    • HIV/AIDS
    • COVID-19
  • 市场魅力分析，各适应症

第8章 全球融合抑制剂市场分析与预测，各流通管道

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测，各流通管道，2017年～2031年
    • 零售药局
    • 线上药局
    • 其他
  • 市场魅力分析，各流通管道

第9章 全球融合抑制剂市场分析与预测，各地区

  • 主要调查结果
  • 市场价值预测，各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 市场魅力分析，各地区

第10章 北美的融合抑制剂市场分析与预测

第11章 欧洲的融合抑制剂市场分析与预测

第12章 亚太地区的融合抑制剂市场分析与预测

第13章 南美的融合抑制剂市场分析与预测

第14章 中东·非洲的融合抑制剂市场分析与预测

第15章 竞争情形

  • 市场参与企业-竞争矩阵
  • 市场占有率/排行榜分析，各企业，2021年
  • 企业简介
    • Bristol-Myers Squibb Company
    • PeptidePharma
    • Incyte
    • Astrazeneca
    • ViiV Healthcare Limited
    • Frontier Bio Corporation
    • Trimeris, Inc.
    • Progenics Pharmaceuticals
    • Schering-Plough(Merck &Co.)
    • Biogen
    • Vanderbilt University
    • Genentech
Product Code: TMRGL85266

The report provides revenue of the global fusion inhibitors market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fusion inhibitors market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fusion inhibitors market.

The report delves into the competitive landscape of the global fusion inhibitors market. Key players operating in the global fusion inhibitors market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global fusion inhibitors market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fusion Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fusion Inhibitors Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Mergers & Acquisitions
  • 5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. Drug Pricing Analysis
  • 5.4. Pipeline Analysis
  • 5.5. Covid-19 Pandemic Impact on the Industry

6. Global Fusion Inhibitors Market Analysis and Forecast, by Route of Administration

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Attractiveness Analysis, by Route of Administration

7. Global Fusion Inhibitors Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. HIV/AIDS
    • 7.3.2. COVID-19
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Fusion Inhibitors Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Online Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Fusion Inhibitors Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Fusion Inhibitors Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. HIV/AIDS
    • 10.3.2. COVID-19
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Retail Pharmacies
    • 10.4.2. Online Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Route of Administration
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Fusion Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.2.1. Oral
    • 11.2.2. Parenteral
  • 11.3. Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. HIV/AIDS
    • 11.3.2. COVID-19
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Retail Pharmacies
    • 11.4.2. Online Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Route of Administration
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Fusion Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.2.1. Oral
    • 12.2.2. Parenteral
  • 12.3. Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. HIV/AIDS
    • 12.3.2. COVID-19
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Retail Pharmacies
    • 12.4.2. Online Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Route of Administration
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Fusion Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.2.1. Oral
    • 13.2.2. Parenteral
  • 13.3. Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. HIV/AIDS
    • 13.3.2. COVID-19
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Retail Pharmacies
    • 13.4.2. Online Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Route of Administration
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Fusion Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.2.1. Oral
    • 14.2.2. Parenteral
  • 14.3. Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. HIV/AIDS
    • 14.3.2. COVID-19
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Retail Pharmacies
    • 14.4.2. Online Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Route of Administration
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share/Ranking Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Bristol-Myers Squibb Company
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Strategic Overview
    • 15.3.2. PeptidePharma
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Strategic Overview
    • 15.3.3. Incyte
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Strategic Overview
    • 15.3.4. Astrazeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Strategic Overview
    • 15.3.5. ViiV Healthcare Limited
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Strategic Overview
    • 15.3.6. Frontier Bio Corporation
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Strategic Overview
    • 15.3.7. Trimeris, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Strategic Overview
    • 15.3.8. Progenics Pharmaceuticals
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Strategic Overview
    • 15.3.9. Schering-Plough (Merck & Co.)
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Strategic Overview
    • 15.3.10. Biogen
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Strategic Overview
    • 15.3.11. Vanderbilt University
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Strategic Overview
    • 15.3.12. Genentech
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Strategic Overview

List of Tables

  • Table 01: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 02: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by 2017-2031, by Indication
  • Table 03: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 07: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 08: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 11: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 16: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 24: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Fusion Inhibitors Market Value Share, by Route of Administration, 2021
  • Figure 03: Global Fusion Inhibitors Market Value Share, by Indication, 2021
  • Figure 04: Global Fusion Inhibitors Market Value Share, by Distribution Channel, 2021
  • Figure 05: Global Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 06: Global Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 09: Global Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 10: Global Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 11: Global Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 12: Global Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 13: Global Fusion Inhibitors Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 14: Global Fusion Inhibitors Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 15: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: North America Fusion Inhibitors Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 17: North America Fusion Inhibitors Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 18: North America Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 19: North America Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 20: North America Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 21: North America Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 22: North America Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 23: North America Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 24: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: Europe Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 26: Europe Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 27: Europe Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 28: Europe Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 29: Europe Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 30: Europe Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 31: Europe Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 32: Europe Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 37: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 38: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 39: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 40: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 43: Latin America Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 45: Latin America Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 46: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 47: Latin America Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 48: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 49: Latin America Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 50: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 54: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 55: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 56: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 57: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 58: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 59: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Company Share Analysis, 2021